Omeros Corporation Reports Positive Q2 Earnings with Reduced Net Loss, Extended Debt Maturity, and Progress in Narsoplimab Approval

Omeros Corporation reported a Q2 net loss of $25.4 million, a significant improvement from Q1. The company extended its debt maturity profile and raised $20.6 million through a registered direct offering. Narsoplimab's regulatory progress includes FDA acceptance of its resubmitted Biologics License Application and a revised PDUFA date of December 26, 2025. European regulatory progress includes submission and validation of the Marketing Authorization Application for narsoplimab in TA-TMA. The FDA extended the PDUFA date for narsoplimab, reflecting the thoroughness of the regulatory review process.